BRIEF-Eli lilly says Solanezumab did not meet primary endpoint in expedition3 clinical trial
December 09, 2016 at 06:40 AM EST
* Will not pursue regulatory submissions for Solanezumab for treatment of mild dementia due to AD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.